J. Kashyap

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

Multiple Sclerosis – An Ophthalmologist ’ s perspective

H. Shekhar, M. Vanathi, J. Titiyal, 2013 .